See more : Professional Holding Corp. (PFHD) Income Statement Analysis – Financial Results
Complete financial analysis of Omeros Corporation (OMER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Omeros Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Nampak Limited (NPK.JO) Income Statement Analysis – Financial Results
- Zhejiang Jihua Group Co., Ltd. (603980.SS) Income Statement Analysis – Financial Results
- Thoughtworks Holding, Inc. (TWKS) Income Statement Analysis – Financial Results
- Stifel Financial Corp. (SF) Income Statement Analysis – Financial Results
- Gloster Ltd (GLOSTERLTD.BO) Income Statement Analysis – Financial Results
Omeros Corporation (OMER)
About Omeros Corporation
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 73.81M | 111.81M | 29.87M | 64.83M | 41.62M | 13.51M | 539.00K | 1.60M | 6.02M | 4.52M | 2.11M | 1.44M | 1.17M | 1.92M | 200.00K | 0.00 |
| Cost of Revenue | 69.78M | 952.00K | 1.39M | 902.00K | 865.00K | 512.00K | 1.08M | 1.41M | 1.04M | 26.73M | 18.33M | 18.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -69.78M | -952.00K | -1.39M | 72.91M | 110.94M | 29.36M | 63.75M | 40.21M | 12.47M | -26.19M | -16.73M | 6.00M | 4.52M | 2.11M | 1.44M | 1.17M | 1.92M | 200.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 98.78% | 99.23% | 98.29% | 98.34% | 96.61% | 92.29% | -4,858.81% | -1,045.38% | 99.69% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 114.87M | 112.72M | 118.78M | 110.82M | 109.70M | 89.86M | 55.60M | 50.70M | 48.38M | 47.95M | 36.30M | 31.92M | 23.72M | 23.47M | 16.93M | 17.85M | 15.92M | 20.53M | 5.80M |
| General & Administrative | 0.00 | 50.67M | 54.84M | 72.70M | 64.63M | 51.72M | 52.04M | 43.78M | 35.33M | 22.60M | 15.82M | 10.99M | 8.22M | 8.75M | 0.00 | 7.85M | 10.40M | 3.63M | 0.00 |
| Selling & Marketing | 0.00 | 3.20K | 7.80K | 5.60K | 8.00K | 2.50M | 300.00K | 672.00K | 885.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.66M | 50.67M | 54.84M | 72.70M | 64.63M | 51.72M | 52.04M | 43.78M | 35.33M | 22.60M | 15.82M | 10.99M | 8.22M | 8.75M | 5.27M | 7.85M | 10.40M | 3.63M | 1.90M |
| Other Expenses | -69.78M | 0.00 | 1.74M | 654.00K | 1.55M | 1.78M | 1.44M | 945.00K | 1.03M | -207.00K | 574.00K | 130.00K | 0.00 | 0.00 | 0.00 | 372.00K | -125.00K | 179.00K | 0.00 |
| Operating Expenses | 94.75M | 163.39M | 173.62M | 183.51M | 174.32M | 141.58M | 107.64M | 94.48M | 83.71M | 70.55M | 52.12M | 42.91M | 31.93M | 32.21M | 22.20M | 25.70M | 26.32M | 24.15M | 7.71M |
| Cost & Expenses | 164.53M | 163.39M | 173.62M | 184.41M | 175.19M | 142.09M | 108.72M | 95.89M | 84.75M | 70.55M | 52.12M | 42.91M | 31.93M | 32.21M | 22.20M | 25.70M | 26.32M | 24.15M | 7.71M |
| Interest Income | 0.00 | 4.06M | 17.93K | 654.00K | 22.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 333.00K |
| Interest Expense | 14.50M | 22.70M | 19.67M | 26.75M | 22.66M | 16.25M | 11.03M | 7.82M | 3.57M | 3.47M | 2.37M | 1.73M | 1.88M | 1.54M | 2.20M | 335.00K | 151.00K | 91.00K | 0.00 |
| Depreciation & Amortization | 920.00K | 952.00K | 1.39M | 1.62M | 1.79M | 962.00K | 551.00K | 300.00K | 209.00K | 326.00K | 302.00K | 320.00K | 435.00K | 472.00K | 451.00K | 434.00K | 375.00K | 232.00K | 341.00K |
| EBITDA | -163.61M | -162.44M | -172.23M | -168.02M | -144.25M | -122.47M | -41.90M | -58.63M | -71.31M | -69.88M | -37.13M | -36.40M | -26.23M | -27.24M | -18.44M | -24.09M | -22.57M | -22.45M | -7.37M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -148.95% | -55.30% | -369.76% | -65.48% | -128.15% | -519.71% | -13,026.90% | -3,102.50% | -610.35% | -612.80% | -1,521.33% | -1,535.87% | -2,027.26% | -1,255.69% | -11,771.00% | 0.00% |
| Operating Income | -164.53M | -163.39M | -173.62M | -110.60M | -63.38M | -112.22M | -43.90M | -54.28M | -71.24M | -70.01M | -50.52M | -36.89M | -27.41M | -30.11M | -20.76M | -24.53M | -24.40M | -23.95M | -7.71M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -149.84% | -56.69% | -375.73% | -67.71% | -130.42% | -527.34% | -12,988.50% | -3,157.25% | -612.50% | -605.88% | -1,430.21% | -1,437.53% | -2,096.15% | -1,268.69% | -11,976.50% | 0.00% |
| Total Other Income/Expenses | -10.39M | -18.64M | -17.93M | -39.47M | -21.10M | -27.46M | -9.59M | -12.47M | -3.86M | -3.67M | 10.72M | -1.56M | -1.14M | 855.00K | -331.00K | 698.00K | 1.31M | 1.18M | 341.00K |
| Income Before Tax | -174.92M | -182.03M | -191.55M | -150.07M | -84.49M | -139.69M | -53.48M | -66.75M | -75.10M | -73.67M | -39.80M | -38.44M | -26.66M | -27.72M | -18.89M | -23.83M | -23.09M | -22.78M | -7.37M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -203.31% | -75.57% | -467.68% | -82.50% | -160.38% | -555.90% | -13,668.46% | -2,487.25% | -638.39% | -589.35% | -1,316.67% | -1,307.96% | -2,036.50% | -1,200.78% | -11,388.50% | 0.00% |
| Income Tax Expense | 0.00 | -210.81M | -365.76M | -12.01M | 22.42M | -12.93M | 11.92M | 8.46M | 4.39M | 2.94M | 2.94M | 1.54M | 1.14M | -855.00K | 331.00K | 707.00K | 26.00K | 270.00K | 0.00 |
| Net Income | -117.81M | 28.78M | 194.24M | -138.06M | -106.91M | -126.76M | -53.48M | -66.75M | -75.10M | -73.67M | -39.80M | -38.44M | -28.55M | -29.25M | -21.09M | -23.83M | -23.09M | -22.78M | -7.37M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -187.04% | -95.62% | -424.39% | -82.50% | -160.38% | -555.90% | -13,668.46% | -2,487.25% | -638.39% | -630.99% | -1,389.60% | -1,460.46% | -2,036.50% | -1,200.78% | -11,388.50% | 0.00% |
| EPS | -1.88 | 0.46 | 3.12 | -2.41 | -2.16 | -2.61 | -1.17 | -1.65 | -2.00 | -2.22 | -1.39 | -1.59 | -1.29 | -1.37 | -2.92 | -8.26 | -1.62 | -1.60 | -0.52 |
| EPS Diluted | -1.88 | 0.46 | 3.12 | -2.41 | -2.16 | -2.61 | -1.17 | -1.65 | -2.00 | -2.22 | -1.39 | -1.59 | -1.29 | -1.37 | -2.92 | -8.26 | -1.62 | -1.60 | -0.52 |
| Weighted Avg Shares Out | 62.74M | 62.74M | 62.34M | 57.18M | 49.52M | 48.58M | 45.54M | 40.45M | 37.56M | 33.23M | 28.56M | 24.16M | 22.21M | 21.42M | 7.22M | 2.88M | 14.27M | 14.27M | 14.27M |
| Weighted Avg Shares Out (Dil) | 62.74M | 62.74M | 62.34M | 57.18M | 49.52M | 48.58M | 45.54M | 40.45M | 37.56M | 33.23M | 28.56M | 24.16M | 22.21M | 21.42M | 7.22M | 2.88M | 14.27M | 14.27M | 14.27M |
Omeros Corporation Reports First Quarter 2022 Financial Results
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
Omeros: The Weight Of The Wait, A Conundrum
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
Omeros Corporation's (OMER) CEO Greg Demopulos on Q4 2021 Results - Earnings Call Transcript
Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results
Why Earnings Season Could Be Great for Omeros (OMER)
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
Omeros: Despite Its Promise, The CRL Is A Huge Obstacle
Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA
Source: https://incomestatements.info
Category: Stock Reports